Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was granted a Family 4 patent by the Japan Patent Office for its anti-infectives, with expiry in 2041.
'We are encouraged by the Japan Patent Office's formal recognition of Recce's new class of anti-infectives,' said James Graham, Chief Executive Officer of Recce Pharmaceuticals. 'Global patent protection underscores our commitment to addressing critical unmet medical needs with innovative therapies. We are well-positioned to deliver meaningful solutions for patients worldwide.'
The Japan Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), including:
Process for preparation of RECCE® anti-infectives
Use of R327/R529 for the treatment of disease, particularly the treatment of bacterial infections, viral infections, and more
Specifically, further validating RECCE® anti-infectives from studies in acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections (DFI), burn wounds, lung infections (i.e., ventilator-associated pneumonia/hospital-acquired pneumonia), urinary tract infections, gonorrhoea, influenza, and SARS-CoV2
Administration by oral, inhalation, transdermal delivery, or by injection (into the bloodstream, intramuscular, and/or intravenous)
Administration may also be applied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery)
This is the fourth Family 4 patent, alongside Australia, Canada, and Israel, with further Patent Cooperation Treaty Country (PCT) submissions in respective stages of review/allowed.
Japan is the third largest pharmaceutical market in the world,1 with a share of approximately 5% of the global pharmaceutical market.2 The antibiotic resistance market in Japan is expected to reach a projected revenue of $411.3 million by 2030. The Japanese antibiotic resistance market expects a compound annual growth rate of 6.1% from 2024 to 2030.3
About Recce Pharmaceuticals LtdRecce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.
Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Corporate ContactJames GrahamRecce Pharmaceuticals Ltd+61 (02) 9256 2571James.graham@recce.com.au
Media & Investor Relations (AU)Andrew GeddesCityPR+61 (02) 9267 4511ageddes@citypublicrelations.com.au
Media (USA)Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com
Investor Relations (USA & EU)Guillaume van RenterghemLifeSci Advisorsgvanrenterghem@lifesciadvisors.com
1 https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals2 https://www.statista.com/statistics/275535/distribution-of-global-pharmaceutical-market-revenue/ 3 https://www.grandviewresearch.com/horizon/outlook/antibiotic-resistance-market/japanSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Top ASX Penny Stocks To Watch In June 2025
The Australian market is bracing for a slight downturn, with ASX 200 futures indicating a -0.2% slide amid geopolitical tensions involving the U.S. and Iran, and mixed economic signals from Europe and Russia. In such uncertain times, investors often look toward penny stocks—an investment area that remains relevant despite its somewhat outdated terminology—for potential growth opportunities in smaller or newer companies. These stocks can offer a mix of affordability and potential when backed by strong financial health, making them intriguing options for those seeking to explore under-the-radar opportunities in the market. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$2.31 A$108.97M ★★★★★★ GTN (ASX:GTN) A$0.615 A$117.37M ★★★★★★ IVE Group (ASX:IGL) A$2.72 A$419.37M ★★★★★☆ West African Resources (ASX:WAF) A$2.19 A$2.5B ★★★★★★ Southern Cross Electrical Engineering (ASX:SXE) A$1.71 A$452.14M ★★★★★★ Tasmea (ASX:TEA) A$3.19 A$751.63M ★★★★★☆ Regal Partners (ASX:RPL) A$2.11 A$709.31M ★★★★★★ Lindsay Australia (ASX:LAU) A$0.69 A$218.85M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.26 A$154.69M ★★★★★★ CTI Logistics (ASX:CLX) A$1.735 A$139.74M ★★★★☆☆ Click here to see the full list of 1,007 stocks from our ASX Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Brazilian Rare Earths Limited is engaged in the exploration of rare earth elements and other critical minerals in Brazil, with a market cap of A$571.20 million. Operations: Currently, there are no reported revenue segments for Brazilian Rare Earths Limited. Market Cap: A$571.2M Brazilian Rare Earths Limited, with a market cap of A$571.20 million, remains pre-revenue and unprofitable but has shown significant progress in its exploration activities. Recent milestones include the successful production of mixed-rare earth carbonate and uranium peroxide from the Monte Alto Project, highlighting potential for high-value product streams like NdPr oxide and uranium yellowcake. The Sulista Project has confirmed ultra-high-grade deposits, expanding exploration potential. Despite being debt-free with no long-term liabilities, BRE's management team is relatively inexperienced. However, it maintains a stable cash runway exceeding one year to support ongoing development efforts. Get an in-depth perspective on Brazilian Rare Earths' performance by reading our balance sheet health report here. Assess Brazilian Rare Earths' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Rand Mining Limited is involved in the exploration, development, and production of mineral properties in Australia with a market cap of A$120.01 million. Operations: The company generates revenue from its Metals & Mining segment, specifically in Gold & Other Precious Metals, amounting to A$41.11 million. Market Cap: A$120.01M Rand Mining Limited, with a market cap of A$120.01 million, benefits from stable weekly volatility and a seasoned management team averaging 22.4 years of tenure. The company has shown consistent earnings growth over the past five years at 19.5% annually, outperforming the industry average last year with a 16.8% increase in earnings despite a slight deceleration from its historical rate. Rand Mining's financial health is robust, as it remains debt-free with short-term assets covering both short- and long-term liabilities comfortably. However, its return on equity remains low at 8.8%, and net profit margins have slightly decreased to 21.6%. Navigate through the intricacies of Rand Mining with our comprehensive balance sheet health report here. Gain insights into Rand Mining's historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Simonds Group Limited, along with its subsidiaries, is involved in the design, construction, and sale of residential dwellings in Australia and has a market cap of A$59.38 million. Operations: The company's revenue is primarily generated from its Residential Construction segment, amounting to A$644.56 million. Market Cap: A$59.38M Simonds Group Limited, with a market cap of A$59.38 million, has recently become profitable, though its earnings growth rate is difficult to compare due to past losses. The company maintains strong financial health with short-term assets exceeding both short- and long-term liabilities and more cash than total debt. However, its interest coverage ratio remains below ideal levels at 2.9x EBIT. Recent executive changes include the appointment of Rhett Simonds as CEO and strategic board adjustments aimed at enhancing financial oversight. Despite trading significantly below estimated fair value, the company's share price has been highly volatile recently. Jump into the full analysis health report here for a deeper understanding of Simonds Group. Examine Simonds Group's past performance report to understand how it has performed in prior years. Jump into our full catalog of 1,007 ASX Penny Stocks here. Looking For Alternative Opportunities? Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BRE ASX:RND and ASX:SIO. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Business Upturn
2 hours ago
- Business Upturn
Food Lyophilization Equipment Market Set to Hit USD 1.60 Billion by 2030
By GlobeNewswire Published on June 20, 2025, 04:30 IST Delray Beach, FL, June 19, 2025 (GLOBE NEWSWIRE) — The global appetite for clean, convenient, and nutrient-rich food is reshaping the way food is preserved—and freeze-drying is stepping up. The global food lyophilization equipment market, valued at USD 1.19 billion in 2025, is projected to reach USD 1.60 billion by 2030, growing at a CAGR of 6.0%. What's Driving the Surge? Modern consumers want it all—taste, nutrition, convenience, and shelf life. Freeze-drying delivers just that, removing moisture from food without compromising its integrity. As a result, food brands are investing in lyophilization equipment to offer products that are: Preservative-free Shelf-stable Nutrient-dense Clean-label compliant This trend is particularly strong in urban centers and export markets where longer shelf life and natural ingredient integrity matter. E-commerce and DTC Fueling Growth The rise of online grocery shopping, meal kits, and direct-to-consumer (DTC) food brands is opening massive opportunities for freeze-dried foods. These channels demand: Lightweight, compact packaging Long shelf life Reliable quality through long-distance shipping Freeze-dried foods check all the boxes, making lyophilization equipment essential for food brands going digital. As startups and mid-sized players scale, they increasingly turn to: Modular systems for flexibility Automated freeze-dryers for efficiency Small-batch setups for pilot production This is creating new demand for scalable, compact systems tailored for DTC growth. Request Personalized Data Insights for Your Business Goals Asia Pacific: The Next Freeze-Drying Powerhouse Expect the Asia Pacific region to lead the global growth curve, clocking the highest CAGR through 2030. Here's why: Urbanization and rising incomes are shifting diets toward packaged foods. China, India, and Southeast Asia are seeing surging demand for healthy, ready-to-eat, long-lasting products. Government support, infrastructure investment, and cost-effective manufacturing attract global players. Food safety awareness is rising, prompting companies to adopt advanced freeze-drying technologies. The region is also emerging as a contract manufacturing hub for freeze-dried products—another signal of the boom ahead. Why Lab-Scale Equipment Is Leading ? Lab-scale lyophilization units currently dominate the food lyophilization equipment industry, and for good reason. They're the go-to choice for: R&D teams testing new recipes Startups validating product-market fit Universities exploring food science innovation These compact units are: Cost-effective Easy to operate Ideal for small-batch experimentation Equipped with adjustable settings for optimal testing As innovation accelerates, these systems are key to launching successful freeze-dried snacks, fruits, dairy, and ready-to-eat meals. Key Questions Addressed by Food Lyophilization Equipment Market Report What are the fastest-growing food segments adopting lyophilization? How do regional regulations impact equipment adoption rates? What adjacent markets are influencing technology trends in food lyophilization? What technological innovations are driving food lyophilization growth now? Why is Asia-Pacific expected to lead the food lyophilization market? What are the main challenges in scaling up food freeze-drying technology? How do automation and energy efficiency influence equipment adoption? Leading Players Shape the Global Food Lyophilization Equipment Market GEA Group Aktiengesellschaft (Germany), Hosokawa Micron Powder Systems (US), Tofflon Science and Technology Group Co., Ltd (China), Spincotech (India), and Martin Christ Gefriertrocknungsanlagen GmbH (Germany). Stay ahead with expert insights on Food Lyophilization Equipment Companies and innovations. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
2 hours ago
- Business Upturn
Native Greens Launches Updated Website Section Featuring Daily Superfood Blend for Adult Wellness Support
San Francisco, June 19, 2025 (GLOBE NEWSWIRE) — Native Greens, a U.S.-based wellness brand focused on natural daily health support, has announced a new update to its official product website. The revised online section now features detailed product information, ingredient transparency, usage guidance, and direct ordering options for the company's popular superfood supplement blend. The update reflects Native Greens' commitment to making wellness support easier and more accessible for adults seeking convenient, plant-based solutions. The refreshed web experience includes a streamlined layout, expanded FAQs, and clearer purchasing pathways for new and returning customers. Website Update Offers Enhanced Navigation and Education The digital refresh, introduced in June 2025, was developed to help health-conscious consumers quickly access the most relevant product information. Visitors can now explore Native Greens' intended uses, ingredient sourcing, quality standards, and customer satisfaction policies in greater detail. The platform update also highlights the brand's continued emphasis on transparency, providing clear descriptions of what the formula contains and how it's intended to integrate into everyday routines. What Is Native Greens? Native Greens is a daily powdered superfood blend created for adults looking to supplement their diets with nutrient-dense, organic plant compounds. While not intended to diagnose or treat any medical condition, the formula is positioned as a food-based option to support general wellness when used consistently as part of a healthy lifestyle. Each serving mixes easily with water or smoothies, offering a quick and flexible addition to morning or midday routines. Ingredients and Intended Use According to the official product page ( the formula features 21 certified organic ingredients, including: Leafy Greens & Grasses : Spinach, kale, broccoli, wheatgrass, barley grass, alfalfa : Spinach, kale, broccoli, wheatgrass, barley grass, alfalfa Algae & Marine Greens : Spirulina, chlorella, kelp : Spirulina, chlorella, kelp Root & Fruit Powders : Beetroot, turmeric, ginger, blueberry, pomegranate, acai, coconut water : Beetroot, turmeric, ginger, blueberry, pomegranate, acai, coconut water Botanicals & Herbal Support: Astragalus, parsley, rosemary, spearmint, chia, apple fiber These ingredients were selected to align with common adult wellness goals such as energy maintenance, digestion support, and antioxidant intake. Native Greens is dairy-free, gluten-free, soy-free, non-GMO, and contains no added sugars, artificial sweeteners, or nightshades. Quality Assurance and Customer Satisfaction Native Greens is manufactured in a cGMP-certified facility in the United States and undergoes third-party testing. Each batch is accompanied by a Certificate of Analysis (COA) to validate product integrity and safety. These details are now highlighted on the updated product page to help customers make informed choices. To further support customer confidence, the brand offers a 365-day money-back guarantee. This satisfaction policy allows first-time buyers to try the product risk-free and return it if not satisfied. Purchasing and Availability Native Greens is available for purchase exclusively through the company's official website. The updated storefront now offers: Tiered pricing based on volume Secure checkout and encrypted transactions Clear return instructions and customer support access The supplement is currently available for U.S. customers, with potential expansion based on demand. Wellness Support Made Simple The updated website underscores the company's belief that health-supportive habits should be simple, flexible, and sustainable. Native Greens is designed to fit seamlessly into modern lifestyles, requiring minimal prep time and no restrictive diet changes. Future updates are expected to include additional educational resources on wellness habits and nutrition, building on the company's effort to create an informative and supportive experience for health-conscious adults. About Native Greens Native Greens is a wellness brand based in the United States, focused on providing clean, easy-to-use dietary supplements that promote daily health support. Through simple formulations and transparent product labeling, the company empowers adults to maintain consistent wellness habits backed by ingredient quality and manufacturing integrity. To learn more, visit: Contact Disclaimer This press release is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration. Native Greens is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always consult a qualified healthcare provider before starting any new dietary supplement, especially if pregnant, nursing, or taking prescription medications. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
